Mechanism affecting risk of prostate cancer is found

January 13, 2014

A research group at Biocenter Oulu in Finland has identified a mechanism related to a transcription factor that binds much more strongly onto a particular SNP variant, thereby initiating a genetic programme which enhances prostate cancer proliferation and metastasis. The study opens up an important new direction in investigating the mechanisms related to the way in which SNP variations cause an elevated risk of prostate cancer and other human diseases. Published in Nature Genetics, the study was partly funded by the Academy of Finland.

Prostate cancer is the most commonly diagnosed malignancy and the second most common cause of cancer-related deaths in men worldwide. In Finland, more than 4,000 new cases are diagnosed every year.

The human genome is mainly identical throughout the human population worldwide. However, millions of small variations or polymorphisms, often located in a single nucleotide, can be found between individuals. These variations are known as single nucleotide polymorphisms (SNP). Using DNA samples from tens of thousands of prostate cancer patients and healthy men, comparative genetic studies, known as genome-wide association studies, have identified dozens of SNPs associated with the risk of prostate cancer. However, because most of these SNPs are not found in the protein-coding regions of the genome, finding the genes that contribute to the risk of prostate cancer is difficult. For this reason, the question of how these single nucleotide genetic variations or SNPs lead to a risk of prostate cancer has not yet been answered.

The research for this international and multidisciplinary study was led by Junior Investigator Gonghong Wei, with a team of scientists from several universities and research institutes. These included three universities in Finland (Oulu, Tampere and Helsinki), Karolinska Institutet in Sweden and Fudan University in China.
-end-
More information:

Gonghong Wei, tel, +358 50 4288 121, gonghong.wei@oulu.fi

Nature Genetics article: http://www.nature.com/ng/journal/vaop/ncurrent/full/ng.2862.html

Academy of Finland Communications
Communications Specialist Leena Vähäkylä
tel. +358 295 335 139
firstname.lastname(at)aka.fi

Academy of Finland

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.